Navigation Links
Statement on Comparative Effectiveness Research Under Senate Appropriations Committee Stimulus Bill
Date:1/27/2009

Language a Step Forward for Patient-Provider Decision Making

Further Action Needed to Ensure Research Reflects America

WASHINGTON, Jan. 27 /PRNewswire-USNewswire/ -- "The Senate today improved on a comparative effectiveness research (CER) package from the House by focusing the $1.1 billion dollar research effort on clinical effectiveness," said Dr. Jane L. Delgado, President and CEO of the National Alliance for Hispanic Health, the nation's leading Hispanic health advocacy group. She added, "The Senate Appropriations Committee has rejected House report language that put cost over quality and was a prescription for bad health.

"House stimulus package language had urged that those treatments found 'more expensive, will no longer be prescribed.' The Senate instead calls for the CER program to focus specifically on clinical effectiveness. The Senate language recognizes that a decision on the best treatment for an individual patient must be made between the patient and their provider, not a federal research or rulemaking body.

"While the Senate language is an improvement , it is important that further steps be taken to ensure that research and governance reflect those that the research seeks to serve."

According to Dr. Delgado two outstanding issues are critical.

1. Final legislation must specifically enforce current policies for inclusion in research. House language was silent on inclusion of gender, race, ethnicity, and disability. While the Senate improves on House language, the final legislation should specifically call for research to be in compliance with the federal Agency for Healthcare Research and Quality Policy on the Inclusion of Priority Populations in Research.

2. Governance must be changed from an all federal board to include majority governance by patient and provider groups. Current House language calls for a 15 person governance board of only federal officials to oversee the $1.1 billion CER program. An all federal panel will not reflect the real-life concerns of patients and providers and inevitably lead to science and spending that does not meet the needs of patients for better quality care.

"We appreciate the work of the Senate Appropriations and Finance Committees and in particular thank Senators Baucus, Conrad, Harkin, and Inouye for their leadership on improving the CER program under the stimulus package. We look forward to our work with the Senate and House in the days ahead to develop a package that puts patients and quality first."

About the National Alliance for Hispanic Health

The National Alliance for Hispanic Health is the nation's foremost source of information and trusted advocate for the health of Hispanics in the United States. The Alliance represents thousands of Hispanic health providers across the nation providing services to more than 15 million each year, making a daily difference in the lives of Hispanic communities and families. For more information, visit http://www.hispanichealth.org or call the Alliance's Su Familia National Hispanic Family Health Helpline at 1-866-783-2645.


'/>"/>
SOURCE National Alliance for Hispanic Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Psychoanalysts Approve Position Statement on Homosexuals and Bisexuals Serving in the Military
2. American Life League Statement on Pelosis State-Enforced War on Preborn Babies
3. Statement on Presidential Memorandum to EPA to Review Lifting of Ban on California Clean Car Standard
4. Endocare Announces Filing of Form S-4 Registration Statement Related to Proposed Merger With Galil Medical
5. Pelosi Statement on Obama Executive Order Repealing Global Gag Rule
6. Catholics for Choice Statement on Overturning the Mexico City Policy
7. UHW Statement on Ray Marshall Trusteeship Recommendations
8. Pelosi Statement on the 36th Anniversary of Roe v. Wade
9. Statement by UHW on SEIUs Claims Regarding SEIU-Trusteeship Hearing Process Chaired by Ray Marshall
10. Capital Blue Cross Issues Statement on Withdrawal of Merger
11. The LCA-Vision Full Value Committee Files Preliminary Consent Solicitation Statement to Reconstitute the Board of Directors of LCA-Vision Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... The Behavioral Health Center of Excellence ... organization as a top behavioral service provider in the country. The award celebrates ... satisfaction and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging ...
(Date:12/6/2016)... Cary, NC (PRWEB) , ... December 06, 2016 ... ... cancer research charity, is thrilled to formally announce its Not a Moment to ... Moment to Lose will rally supporters dedicated to declaring victory over cancer. The ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... is now offering HIAC particle counting and sizing services for USP 788 and ... instituted the new service as a response to the needs of pharmaceutical and ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble ... Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... NEW YORK , Dec. 5, 2016 /PRNewswire/ ... of penicillin in 1948, antibiotics have emerged as ... treating several infectious conditions. In addition, antibiotics are ... have undergone surgery, or immunocompromised patients (cancer patients ... both in healthcare and food production, has rapidly ...
(Date:12/5/2016)... 29, 2016 Several leading Alzheimer,s disease experts ... Inc. at 11 a.m. EST on December 6 ... Clinical Trials for Alzheimer,s Disease (CTAD). The program will ... disease and therapeutic targets that address deficient glucose metabolism ... recent failure of another therapy targeting the amyloid hypothesis, ...
(Date:12/5/2016)... Research and Markets has announced the addition of the ... Research, Disease Diagnostics), End User (Academic & Research Institutes, Pharmaceutical & ... offering. ... The western blotting market is expected ... in 2016, growing at a CAGR of 4.9%. ...
Breaking Medicine Technology: